EUVIMEDEUVIMED entdecken
Fallbericht

Expanding the role of avacopan beyond renal involvement: Clinical insights from two cases

Andreia Rita Henriques iD, Nuno Oliveira iD, Pedro Castro iD, Helena Pinto iD, Emanuel Ferreira iD, Helena Sá

Modern Rheumatology Case Reports · 06.01.2026 · 10 (1)

DOI: 10.1093/mrcr/rxag022 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, online erschienen am 09.03.2026. Verfasst von Andreia Rita Henriques und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal. Hauptthemen laut MEDLINE: Granulomatosis with Polyangiitis, Receptor, Anaphylatoxin C5a. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Granulomatosis with polyangiitis is a necrotising small vessel vasculitis characterised by granulomatous inflammation that can involve the eyes, ear-nose-throat region, and lungs, often refractory to standard immunosuppressive therapies such as glucocorticoids, rituximab, and cyclophosphamide. The complex immunopathogenesis of granulomatous lesions, involving neutrophil swarming, macrophage activation, T-cell responses, and complement activation through the C5a receptor, contributes to treatment challenges. Avacopan, an oral C5a receptor antagonist, has demonstrated efficacy in antineutrophil cytoplasmic antibody-associated vasculitis, particularly in kidney involvement, with evidence of glucocorticoid-sparing benefits from the ADVOCATE trial. However, data on its role in granulomatous manifestations remain limited. We report two cases of severe, refractory granulomatosis with polyangiitis with ocular, ear-nose-throat, and pulmonary granulomatous disease unresponsive to standard therapies but achieving complete clinical and immunological remission with avacopan. Both patients successfully discontinued glucocorticoids and showed marked clinical improvement and radiological resolution of lesions. These cases, supported by recent trial sub-analyses, suggest that avacopan may be an effective therapeutic option for granulomatous granulomatosis with polyangiitis manifestations, enabling glucocorticoid reduction and improved disease control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulomatosis with PolyangiitisReceptor, Anaphylatoxin C5aFemaleHumansMaleMiddle AgedGlucocorticoidsImmunosuppressive AgentsTreatment OutcomeAgedAniline CompoundsNipecotic Acids

Stichwörter der Autor:innen

ANCA-associated vasculitisAvacopanglucocorticoids sparinggranulomatous manifestationstreatment

Substanzen

avacopanGlucocorticoidsImmunosuppressive AgentsReceptor, Anaphylatoxin C5aAniline CompoundsNipecotic Acids

Autor:innen und Institutionen

  • Nephrology department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
  • University of Coimbra, Faculty of Medicine, Coimbra, Portugal.

ORCID-Profile: Andreia Rita Henriques, Nuno Oliveira, Pedro Castro, Helena Pinto, Emanuel Ferreira

Zitieren

APA

Henriques, A. R., Oliveira, N., Castro, P., Pinto, H., Ferreira, E., & Sá, H. (2026). Expanding the role of avacopan beyond renal involvement: Clinical insights from two cases. Modern Rheumatology Case Reports, 10(1). https://doi.org/10.1093/mrcr/rxag022

Vancouver

Henriques AR, Oliveira N, Castro P, Pinto H, Ferreira E, Sá H. Expanding the role of avacopan beyond renal involvement: Clinical insights from two cases. Modern Rheumatology Case Reports. 2026;10(1). doi:10.1093/mrcr/rxag022

BibTeX
@article{Henriques2026,
  author = {Henriques, Andreia Rita and Oliveira, Nuno and Castro, Pedro and Pinto, Helena and Ferreira, Emanuel and Sá, Helena},
  title = {Expanding the role of avacopan beyond renal involvement: Clinical insights from two cases},
  journal = {Modern Rheumatology Case Reports},
  year = {2026},
  volume = {10},
  number = {1},
  doi = {10.1093/mrcr/rxag022}
}
Kostenlos starten →